Sunday

EU again turns down Teva's laquinimod

Teva and Active Biotech filed a request for a review of the finding. The result is a setback for the two companies. Laquinimod has been considered a replacement for Teva's high-selling multiple sclerosis treatment Copaxone
Click here to read more